29A Stock Chart & Stats
€16.09
-€0.26(-1.59%)
At close: 4:00 PM EDT
€16.09
-€0.26(-1.59%)
Day’s Range― - ―
52-Week Range€13.90 - €25.96
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€762.11M
Enterprise Value€1.30K
Total Cash (Recent Filing)€294.39M
Total Debt (Recent Filing)€686.38M
Price to Earnings (P/E)11.7
Beta0.66
Next Earnings
Aug 06, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.71
Shares Outstanding44,092,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.59
Price to Sales (P/S)1.74
P/FCF Ratio10.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.07Price Target Upside18.52% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.26
Revenue Forecast (FY)€652.90M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent TTM operating cash flow (~$169M) and meaningful free cash flow (~$135M) provide durable internal funding for R&D, capex, share repurchases and working capital. This cash generación supports strategic flexibility through product investment and shields operations from short-term liquidity shocks.
Low Leverage / Solid Balance SheetVery low trailing leverage (debt/equity ~0.10) and sizable equity provide long-term financial flexibility to fund pipeline development, absorb regulatory remediation costs, and pursue selective M&A or licensing without pressuring liquidity or requiring dilutive financing.
Portfolio Expansion And Late-stage PipelineNew product launches like AMP-007 and confirmed late-stage biosimilar/GLP‑1 ANDA timelines create durable future revenue diversification into higher-value, complex dosage forms. Successful commercialization of these assets could sustainably shift mix toward higher-margin, less commoditized products.
Bears Say
Regulatory / GMP Warning LetterAn FDA warning letter to the subsidiary flags systemic manufacturing and quality-control weaknesses. Remediation can require capital and operational disruption, prolong compliance costs, and raise the risk of enforcement actions that could materially constrain manufacturing capacity or increase oversight over several quarters.
Earnings And Margin PressureRising cost of goods and operating expenses alongside falling adjusted and GAAP earnings indicate structural margin compression. If pricing headwinds and higher facility or SG&A costs persist, profitability and cash conversion could remain impaired for multiple quarters, limiting reinvestment capacity.
Competitive Pressure On Legacy ProductsSignificant declines in legacy product revenues reflect durable competitive and channel-rebate pressures in generics (340B, duplicate rebates, ready-to-use entrants). Continued commoditization of older assets can erode revenue stability and force margin trade-offs while relying on newer launches to replace lost cash flows.
Amphastar Pharmaceuticals News
29A FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was €13.90 and its highest was €25.96 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Amphastar Pharmaceuticals’s market cap is €762.11M.
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on May 07, 2026. The company reported €0.364 earnings per share for the quarter, missing the consensus estimate of €0.611 by -€0.247.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is 0.54.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 44,092,920 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of €0.364 in its last earnings report, missing expectations of €0.611. Following the earnings report the stock price went down -9.26%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:29A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amphastar Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€19.07 (18.52% Upside)
€19.07 (18.52% Upside)
Blogger Sentiment
Neutral
DE:29A Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.35%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
29A Company Deck
29A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operational and strategic positives (stable-to-growing total revenue, strong cash flow, successful new product launches, pipeline progress toward 2027, and active share repurchases) are offset by meaningful near-term headwinds (a 15% decline in BAQSIMI revenue driven by rebate/340B pressure, a 56% collapse in glucagon sales, rising costs and higher operating expenses, and materially lower net and adjusted earnings). Management has taken targeted actions (price increase, 340B validation, new product launch, continued R&D investment) to address the issues, but near-term margin and earnings pressure remain evident.View all DE:29A earnings summaries29A Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€19.07
▲(18.52% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―










